Evidence map›Paper›PMID 38145631›Full record

SynthesisJornal de pediatria

Linezolid and vancomycin for nosocomial infections in pediatric patients: a systematic review.

Bruno Russo Porchera, Carolina Moraes da Silva, Rayssa Pinheiro Miranda, Antônio Rafael Quadros Gomes, Pedro Henrique Dos Santos Fernandes, Camili Giseli Oliveira de Menezes, Paula do Socorro de Oliveira da Costa Laurindo, Maria Fani Dolabela, Heliton Patrick Cordovil Brígido

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Jornal de pediatria. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Bruno Russo PorcheraCentro Universitário do Estado do Pará (CESUPA), Curso de Medicina, Belém, PA, Brazil.
Carolina Moraes da SilvaCentro Universitário do Estado do Pará (CESUPA), Curso de Medicina, Belém, PA, Brazil.
Rayssa Pinheiro MirandaCentro Universitário do Estado do Pará (CESUPA), Curso de Medicina, Belém, PA, Brazil.
Antônio Rafael Quadros GomesUniversidade Federal do Pará (UFPA), Programa de Pós-graduação em Inovação Farmacêutica (PPGIF), Belém, PA, Brazil.
Pedro Henrique Dos Santos FernandesFaculdade Cosmopolita, Curso de Farmácia, Belém, PA, Brazil.
Camili Giseli Oliveira de MenezesCentro Universitário Metropolitano da Amazônia (UNIFAMAZ), Curso de Medicina, Belém, PA, Brazil.
Paula do Socorro de Oliveira da Costa LaurindoCentro Universitário Metropolitano da Amazônia (UNIFAMAZ), Curso de Medicina, Belém, PA, Brazil.
Maria Fani DolabelaUniversidade Federal do Pará (UFPA), Programa de Pós-graduação em Inovação Farmacêutica (PPGIF), Belém, PA, Brazil.
Heliton Patrick Cordovil BrígidoUniversidade Federal do Pará (UFPA), Programa de Pós-graduação em Inovação Farmacêutica (PPGIF), Belém, PA, Brazil; Centro Universitário Metropolitano da Amazônia (UNIFAMAZ), Curso de Medicina, Belém, PA, Brazil. Electronic address: helitombrigido@gmail.com.
Centro Universitário do Pará · BRUniversidade da Amazônia · BRUniversidade Federal do Pará · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the effectiveness of linezolid and vancomycin for the treatment of nosocomial infections in children under 12 years old. DATA SOURCES: This is a systematic review in which five randomized clinical trials about the effectiveness of linezolid and vancomycin, involving a total of 429 children with nosocomial infections, were evaluated. They were searched in scientific databases: PubMed, Bvs, and SciELO. SUMMARY OF

findingsThe main nosocomial infections that affected children were bacteremia, skin, and soft tissue infections followed by nosocomial pneumonia. Most infections were caused by Gram-positive bacteria, which all studies showed infections caused by Staphylococcus aureus, with methicillin-resistant S. aureus (MRSA) and methicillin-resistant coagulase-negative staphylococci strains being isolated. Both linezolid and vancomycin showed high therapeutic efficacy against different types of nosocomial infections, ranging from 84.4% to 94% for linezolid and 76.9% to 90% for vancomycin. Patients receiving linezolid had lower rates of rash and red man syndrome compared to those receiving vancomycin. However, despite the adverse reactions, antimicrobials can be safely administered to children to treat nosocomial infections caused by resistant Gram-positive bacteria.

conclusionBoth linezolid and vancomycin showed good efficacy in the treatment of bacterial infections caused by resistant Gram-positive bacteria in hospitalized children. However, linezolid stands out regarding its pharmacological safety. Importantly, to strengthen this conclusion, further clinical trials are needed to provide additional evidence.

Indexed as

Anti-Bacterial AgentsCross InfectionLinezolidVancomycinChildChild, PreschoolGram-Positive Bacterial InfectionsHumansInfantMethicillin-Resistant Staphylococcus aureusRandomized Controlled Trials as TopicStaphylococcal InfectionsAnti-Bacterial AgentsLinezolidVancomycinLinezolidNosocomial infectionsPediatricsVancomycin

Identifiers

PMID38145631
PMCPMC11065658
OpenAlexW4390135133

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.